Startup known as Level Zero Health raised $6.9 million in its pre-seed funding round for its wearable medical device of the same name. The company hopes that the device, capable of conducting hormone tests without blood sampling, will pave the way for new treatments. Utilizing DNA-based sensors, the device developed by Level Zero Health detects hormone levels from interstitial fluid. This technology allows users to continuously monitor their hormone levels, offering a less invasive method compared to traditional blood tests. The sensors collect hormone data regularly, closely tracking the user’s health status and issuing a warning when any abnormality is detected. WHEN WILL IT HIT THE MARKET? The current prototype contains small needles to extract minute hormone samples from just beneath the skin. The device can provide continuous measurements of hormones such as progesterone, estrogen, and testosterone from the user’s interstitial fluid. Level Zero Health is planning to launch in 2028. PURPOSE OF INVESTMENT The company intends to use this investment to support its R&D efforts and expand its team. CEO Ula Rustamova highlights the significant progress this innovative technology has made in hormone testing and mentions that the funds will enable them to bring this revolutionary solution to the market. Rustamova also asserts that the device will create a new product category in the healthcare sector, serving as a foundation for many future companies built upon this device and its data. Level Zero Health initially aims to focus on B2B clinical applications but plans to expand into consumer health and pharmaceutical markets in the future. The company’s technology has the potential to revolutionize various health areas such as IVF, menopause, and testosterone replacement therapy. Furthermore, the data provided by the device will be a valuable resource for researchers and healthcare professionals. MARKET REACTIONS This new technology introduced by Level Zero Health has garnered significant interest in the healthcare sector. Experts suggest that this revolution in hormone testing will enable patients to monitor their health more effectively, leading to increased opportunities for early diagnosis and treatment. Investors are supporting this innovative venture by recognizing the company’s potential. ENTIRELY A WOMAN-LED VENTURE Level Zero Health was founded by former Palantir Technology President Ula Rustamova and Phillips Medical Device Specialist Irene Jia.